Tucatinib (Tukysa®). HTA ID: 22058

Assessment Status Awaiting full HTA submission from Applicant
HTA ID 22058
Drug Tucatinib
Brand Tukysa®
Indication In combination with trastuzumab and capecitabine for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer wo have received at least two prior anti-HER2 treatment regimens.
Assessment Process
Rapid review commissioned 23/08/2022
Rapid review completed 20/09/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tucatinib compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 28/09/2022
Pre-submission consultation with Applicant 12/12/2023

Not recommended due to non-submission of full HTA.